Skip to main content
Erschienen in: Pathology & Oncology Research 4/2016

01.04.2016 | Short Communication

The Uncontrolled Sialylation is Related to Chemoresistant Metastatic Breast Cancer

verfasst von: Luca Roncati, Giuseppe Barbolini, Antonietta Morena Gatti, Teresa Pusiol, Francesco Piscioli, Antonio Maiorana

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Among the scientific communities, there is a convergence of results supporting a direct relationship between dysregulated sialylation and poor prognosis in many human cancers. For this reason, we have retrospectively investigated 169 cases of invasive ductal carcinoma of the breast, coming from female patients aged between 31 and 76 years old. The whole series was subdivided into two prognostic groups: the first group consisted of 138 patients, who showed a post-treatment survival time more than 5 years, while the second group was made up by 31 patients, died within 5 years despite of chemotherapy. All the surgical specimens were fixed in 10 % neutral buffered formalin, paraffin embedded and, then, submitted to routinely haematoxylin/eosin staining and to a further histochemical (Alcian Blue, DDD-Fast Blue B, Mercury Orange), immunohistochemical (ST3GAL5 sialyltransferase, Ki67, c-erbB2, ER, PR) and chemico-elemental characterization. In the 31 cases of breast cancer belonging to the second group, an overexpression of sialomucins and sialyltransferases has been detected. Our results lead us to support that in aggressive chemoresistant breast cancers, the altered expression of sialic acid, due to an uncontrolled sialylation, creates an excessive negative charge on cell membranes, which stimulates repulsion between neoplastic cells and their subsequent access into the blood stream. This event implies an early metastatization and a rapid disease progression with fatal outcome. The early application of Alcian Blue stain on diagnostic biopsies of breast cancer is able to cheaply reveal the sialomucin accumulations, providing for the disease course.
Literatur
1.
Zurück zum Zitat Schauer R (2000) Achievements and challenges of sialic acid research. Glycoconj J 17:485–499CrossRefPubMed Schauer R (2000) Achievements and challenges of sialic acid research. Glycoconj J 17:485–499CrossRefPubMed
2.
Zurück zum Zitat Cazet A, Julien S, Bobowski M, Krzewinski-Recchi MA, Harduin-Lepers A, Groux-Degroote S, et al. (2010) Consequences of the expression of sialylated antigens in breast cancer. Carbohydr Res 345:1377–1383CrossRefPubMed Cazet A, Julien S, Bobowski M, Krzewinski-Recchi MA, Harduin-Lepers A, Groux-Degroote S, et al. (2010) Consequences of the expression of sialylated antigens in breast cancer. Carbohydr Res 345:1377–1383CrossRefPubMed
3.
Zurück zum Zitat Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH (2014) Cell surface protein glycosylation in cancer. Proteomics 14:525–546CrossRefPubMed Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH (2014) Cell surface protein glycosylation in cancer. Proteomics 14:525–546CrossRefPubMed
4.
Zurück zum Zitat Miyagi T, Takahashi K, Hata K, Shiozaki K, Yamaguchi K (2012) Sialidase significance for cancer progression. Glycoconj J 29:567–577CrossRefPubMed Miyagi T, Takahashi K, Hata K, Shiozaki K, Yamaguchi K (2012) Sialidase significance for cancer progression. Glycoconj J 29:567–577CrossRefPubMed
5.
Zurück zum Zitat Gatti AM, Montanari S (2005) Risk assessment of microparticles and nanoparticles and human health. In: Nalwa HS (ed) Handbook of nanostructured biomaterials and their applications in nanobiotechnology. American Scientific Publishers, Portland, pp. 347–369 Gatti AM, Montanari S (2005) Risk assessment of microparticles and nanoparticles and human health. In: Nalwa HS (ed) Handbook of nanostructured biomaterials and their applications in nanobiotechnology. American Scientific Publishers, Portland, pp. 347–369
6.
Zurück zum Zitat Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 41:154–161PubMed Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 41:154–161PubMed
7.
Zurück zum Zitat Tian Y, Esteva FJ, Song J, Zhang H (2012) Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry. Mol Cell Proteomics 11:M111.011403CrossRefPubMedPubMedCentral Tian Y, Esteva FJ, Song J, Zhang H (2012) Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry. Mol Cell Proteomics 11:M111.011403CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, et al. (2008) Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem 54:1166–1175CrossRefPubMed Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, et al. (2008) Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem 54:1166–1175CrossRefPubMed
9.
Zurück zum Zitat Dwek MV, Lacey HA, Leathem AJ (1998) Breast cancer progression is associated with a reduction in the diversity of sialylated and neutral oligosaccharides. Clin Chim Acta 271:191–202CrossRefPubMed Dwek MV, Lacey HA, Leathem AJ (1998) Breast cancer progression is associated with a reduction in the diversity of sialylated and neutral oligosaccharides. Clin Chim Acta 271:191–202CrossRefPubMed
Metadaten
Titel
The Uncontrolled Sialylation is Related to Chemoresistant Metastatic Breast Cancer
verfasst von
Luca Roncati
Giuseppe Barbolini
Antonietta Morena Gatti
Teresa Pusiol
Francesco Piscioli
Antonio Maiorana
Publikationsdatum
01.04.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2016
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0057-6

Weitere Artikel der Ausgabe 4/2016

Pathology & Oncology Research 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.